


European Patent Office
80298 MUNICH
GERMANY
Tel. +49 (0)89 2399 - 0
Fax +49 (0)89 2399 - 4465



Vossius & Partner
Siebertstrasse 4
81675 München
ALLEMAGNE



For any questions about
this communication:

Tel.: +31 (0)70 340 45 00

Date
20.05.08

Reference M2569 EP S3	Application No./Patent No. 05710541.3 - 2123 PCT/JP2005002838
Applicant/Proprietor Dainippon Sumitomo Pharma Co., Ltd.	

Communication

The European Patent Office herewith transmits as an enclosure the supplementary European search report under Article 153(7) EPC for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

- ☒ Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.

Refund of the search fee

If applicable under Article 9 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.





DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	NODA Y ET AL: "CLOZAPINE, BUT NOT HALOPERIDOL, REVERSES WORKING MEMORY IMPAIRMENT INDUCED BY CHRONIC PCP ADMINISTRATION IN RATS: A NEW MODEL FOR COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA" ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 26, no. 1-2, 2000, page ABSTRACTNO6533, XP009067118 ISSN: 0190-5295	1-4	INV. G01N33/50 A61K31/445 A61K31/496 A61K31/551 A61K31/554 A61K45/00 A61P25/18 A61P25/28 A61P43/00 C07D211/32 C07D243/10 C07D281/14
Y	* abstract *	1-5	
X	DIDRIKSEN M ET AL: "ANTIPSYCHOTIC POTENTIAL OF THE GLYT-1 INHIBITOR NFPS." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, pages Abstract No. 893.1 URL-http://sf, XP009099160 & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002	1-4	
Y	* abstract *	1-5	
Y	CORBETT ROY: "Clozapine but not haloperidol antagonists an MK-801 discriminative stimulus cue" PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 51, no. 2-3, 1995, pages 561-564, XP002477936 ISSN: 0091-3057 table 1 and page 562-563, paragraph entitled "Discussion"	1-4	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 24 April 2008	Examiner Borst, Markus
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			



DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)												
Y	WISE L E ET AL: "REVERSAL LEARNING IN THE 8 - ARM RADIAL MAZE IN RATS IS IMPAIRED BY SUBCHRONIC ADMINISTRATION OF THE NONCOMPETITIVE NMDA ANTAGONIST KETAMINE." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, pages Abstract No. 494.7 URL-http://sf, XP009099161 & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002 * abstract *	1-4													
Y	GEYER MARK A ET AL: "Animal behavior models of the mechanisms underlying antipsychotic atypicality." PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 27, no. 7, October 2003 (2003-10), pages 1071-1079, XP002477937 ISSN: 0278-5846 page 1075-1076, paragraph entitled "11.4. The NMDA antagonist PPI model"	1-4	TECHNICAL FIELDS SEARCHED (IPC)												
Y	PUTTRESE G S ET AL: "Localized deletion of the NR1 gene in mouse prefrontal cortex impairs spatial memory." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, pages Abstract No. 964.19 URL-http://sf, XP009099333 & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003 * abstract *	1,5													
The supplementary search report has been based on the last set of claims valid and available at the start of the search.															
Place of search Munich		Date of completion of the search 24 April 2008	Examiner Borst, Markus												
<table border="0"><tr><td>CATEGORY OF CITED DOCUMENTS</td><td>T : theory or principle underlying the invention</td></tr><tr><td>X : particularly relevant if taken alone</td><td>E : earlier patent document, but published on, or after the filing date</td></tr><tr><td>Y : particularly relevant if combined with another document of the same category</td><td>D : document cited in the application</td></tr><tr><td>A : technological background</td><td>L : document cited for other reasons</td></tr><tr><td>O : non-written disclosure</td><td>& : member of the same patent family, corresponding document</td></tr><tr><td>P : intermediate document</td><td></td></tr></table>				CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention	X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date	Y : particularly relevant if combined with another document of the same category	D : document cited in the application	A : technological background	L : document cited for other reasons	O : non-written disclosure	& : member of the same patent family, corresponding document	P : intermediate document	
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention														
X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date														
Y : particularly relevant if combined with another document of the same category	D : document cited in the application														
A : technological background	L : document cited for other reasons														
O : non-written disclosure	& : member of the same patent family, corresponding document														
P : intermediate document															

2
EPO FORM 1503 03/82 (P04C04)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A, D	HARROD S B ET AL: "MK-801 induced retrieval, but not acquisition, deficits for passive avoidance conditioning" PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 69, no. 3-4, July 2001 (2001-07), pages 585-593, XP002477938 ISSN: 0091-3057 table 2 and page 591-59592, paragraph entitled "4. General discussion" -----	1-5	
X	TOKUDA KUMIKO ET AL: "Effects of SM-13496, an atypical antipsychotic agent, on MK-801-induced learning deficit in rats." JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 94, no. Supplement 1, 2004, page 163P, XP009099201 & 77TH ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY; OSAKA, JAPAN; MARCH 08-10, 2004 ISSN: 1347-8613	1-4	
Y	* abstract * -----	1-4	TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 24 April 2008	Examiner Borst, Markus
<div>CATEGORY OF CITED DOCUMENTS</div> <div>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</div> <div>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document</div>			



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:
- ☒ The present supplementary European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims (Rule 164 (1) EPC).



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-5

screening method

2. claims: 6 (part), 7, 17 (part) - 19 (part)

therapeutic agent comprising aricept

3. claims: 6 (part), 8-9, 17 (part) - 19 (part)

therapeutic agent comprising quetiapine

4. claims: 6 (part), 10-11, 17 (part) - 19 (part)

therapeutic agent comprising clozapine

5. claims: 6 (part), 12-15, 17 (part) - 19 (part)

therapeutic agent comprising imide derivative according to
formula [1]

6. claims: 6 (part), 16, 17 (part) - 19 (part)

therapeutic agent comprising a compound according to
formula [2]
